Legend Biotech Corporation
LEGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | -2.21 | -3.48 | -1.23 |
| FCF Yield | -5.32% | -7.85% | -5.63% | -7.43% |
| EV / EBITDA | -26.85 | -9.10 | -8.33 | -6.92 |
| Quality | ||||
| ROIC | -21.70% | -26.78% | -43.95% | -43.63% |
| Gross Margin | 62.60% | 49.42% | 44.14% | 100.00% |
| Cash Conversion Ratio | 0.91 | 0.76 | 0.45 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 75.02% | 60.61% | 15.98% | 4,098,015.33% |
| Free Cash Flow Growth | 61.99% | -86.08% | 8.33% | 3.72% |
| Safety | ||||
| Net Debt / EBITDA | -0.56 | 1.99 | 1.20 | 1.44 |
| Interest Coverage | -14.03 | -20.17 | -42.20 | -435.87 |
| Efficiency | ||||
| Inventory Turnover | 9.81 | 7.42 | 6.31 | 0.00 |
| Cash Conversion Cycle | 51.99 | 199.21 | 19.70 | 310.49 |